CAI · CIK 2019410
What Caris Life Sciences, Inc. told the SEC could break it.
Nearly everything Caris flagged traces back to how narrow its revenue base is: a single product, MI Profile, drove 84.4% of 2025 revenue, and Medicare-covered cases supplied roughly 39.6% of its molecular-profiling revenue — so the company's fortunes ride on one tissue-based test and one government payer. That payer dependence has a regulatory edge: PAMA's rate-setting for the Clinical Laboratory Fee Schedule could cut the Medicare reimbursement Caris leans on. Underneath it sits operational fragility — several sole suppliers for the tubes, extraction kits, and NGS panels its assays require, and a first-lien term loan against a $2.5B accumulated deficit.
5 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- unnamed sole suppliers for blood collection tubes, nucleic acid extraction kits, NGS panels and library prep kitshigh
Beyond Illumina, Caris depends on several other sole suppliers/manufacturers for blood collection tubes, total nucleic acid extraction kits, and the NGS panels and library preparation kits used in its assays; loss of access could halt its ability to run and commercialize solutions.
“We also rely on several sole suppliers, or manufacturers, for blood collection tubes, for total nucleic acid extraction kits, and for the NGS panels and library preparation kits we use.”
SEC filing →As of 2026
Customer concentration
- Medicare = ~39.6% of molecular profiling services revenuemedium
Medicare-covered clinical cases represented ~39.6% of molecular profiling services revenue in 2025, concentrating reimbursement dependence on a single government payer.
“Revenue from clinical cases for patients covered by Medicare represented approximately 39.6% and 39.0% of our molecular profiling services revenue for the years ended December 31, 2025 and 2024, respectively.”
SEC filing →As of 2026
Liquidity & debt
- 2023 Term Loan (first-lien, 12.3% effective rate) amid $2.5B accumulated deficitmedium
Caris carries a 2023 Term Loan secured by a first-lien interest in substantially all assets (including IP) at a 12.3% effective rate, against a $2.5B accumulated deficit; default could let lenders seize collateral.
“Our obligations under the 2023 Term Loan Agreement are secured by a first lien security interest in substantially all of our assets and our subsidiaries' assets.”
SEC filing →As of 2026
Other disclosures
- single-product concentration: MI Profile = 84.4% of revenuemedium
MI Profile, the tissue-based profiling solution, accounted for 84.4% of 2025 revenue, making Caris highly dependent on continued adoption, payer coverage, and guideline inclusion of a single product line.
“Our ability to execute our growth strategy and become profitable is highly dependent on the continued adoption and use of MI Profile, our tissue-based profiling solution, which accounted for 84.4% of our revenue for the year ended December 31, 2025.”
SEC filing →As of 2026
Regulatory & policy
- PAMA / CLFS Medicare lab-test reimbursement rate settingmedium
PAMA's price-setting for the Clinical Laboratory Fee Schedule could cut Medicare reimbursement; Caris must report private-payer data for MI Cancer Seek and Caris Assure in the 2026 PAMA cycle, which could lower their Medicare rates from Jan 1, 2027 (reductions limited to 0% through 2026, 15%/yr 2027-2029).
“We will be required to report private payer data for MI Cancer Seek and Caris Assure in the 2026 PAMA reporting cycle, which could impact Medicare reimbursement rates for these solutions as of January 1, 2027.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“We rely on Illumina, Inc. (“Illumina”) as the sole supplier of NGS instruments and the associated sequencing reagent kits for our solutions. Illumina is also the sole provider of maintenance and repair services for these sequencing instruments.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch